NARS1

Chr 18ARAD

asparaginyl-tRNA synthetase 1

Also known as: ASNRS, NARS, NEDMILEG, NEDMILG

Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their cognate amino acids. Asparaginyl-tRNA synthetase is localized to the cytoplasm and belongs to the class II family of tRNA synthetases. The N-terminal domain represents the signature sequence for the eukaryotic asparaginyl-tRNA synthetases. [provided by RefSeq, Jul 2008]

GeneReviewsOMIMResearchGenerating clinical summary…
MultiplemechanismAR/ADLOEUF 0.782 OMIM phenotypes
Clinical SummaryNARS1
🧬
Gene-Disease Validity (ClinGen)
neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities · ADModerate

Moderate evidence — consider for supplementary testing

2 total gene-disease associations curated

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
23 unique Pathogenic / Likely Pathogenic· 165 VUS of 236 total submissions
📖
GeneReview available — NARS1
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.78LOEUF
pLI 0.000
Z-score 2.62
OE 0.54 (0.380.78)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
0.83Z-score
OE missense 0.87 (0.780.96)
268 obs / 308.9 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.54 (0.380.78)
00.351.4
Missense OE?0.87 (0.780.96)
00.61.4
Synonymous OE?1.04
01.21.6
LoF obs/exp: 20 / 37.2Missense obs/exp: 268 / 308.9Syn Z: -0.34
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongNARS1-related neurodevelopmental disorderGOFAD
definitiveNARS1-related neurodevelopmental disorderLOFAR

This gene — mechanism propensity

DN
0.6745th %ile
GOF
0.6248th %ile
LOF
0.2969th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOF1 literature citation

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFDe Novo and Bi-allelic Pathogenic Variants in NARS1 Cause Neurodevelopmental Delay Due to Toxic Gain-of-Function and Partial Loss-of-Function Effects1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

References

  1. 1.PMID 32738225

ClinVar Variant Classifications

236 submitted variants in ClinVar

Classification Summary

Pathogenic4
Likely Pathogenic19
VUS165
Likely Benign22
Benign2
Conflicting3
4
Pathogenic
19
Likely Pathogenic
165
VUS
22
Likely Benign
2
Benign
3
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
4
0
0
0
4
Likely Pathogenic
9
10
0
0
19
VUS
14
148
3
0
165
Likely Benign
0
7
0
15
22
Benign
0
0
1
1
2
Conflicting
3
Total27165416215

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

68 pathogenic / likely-pathogenic (of 79) ClinVar copy-number / structural variants overlap NARS1 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

NARS1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →